News
ANAB
48.77
+0.81%
0.39
Weekly Report: what happened at ANAB last week (1102-1106)?
Weekly Report · 3d ago
Weekly Report: what happened at ANAB last week (1026-1030)?
Weekly Report · 11/02 09:56
Riverwater Micro Opportunities Strategy Q3 2026 Portfolio Activity
Seeking Alpha · 10/30 09:55
Did Rectal Cancer Approval Just Shift AnaptysBio's (ANAB) Investment Narrative?
Simply Wall St · 10/29 21:50
Diamond Hill Small-Mid Cap Fund Q3 2026 Contributors And Detractors
Seeking Alpha · 10/29 07:50
AnaptysBio (ANAB) Gains From Jemperli Approval, Is The Royalty Upside Already Priced In?
Simply Wall St · 10/27 13:25
Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), Bristol-Myers Squibb (BMY) and Parabilis Medicines, Inc. (PBLS)
TipRanks · 10/26 14:50
Weekly Report: what happened at ANAB last week (1019-1023)?
Weekly Report · 10/26 09:56
Analysts Offer Insights on Healthcare Companies: Celcuity (CELC) and AnaptysBio (ANAB)
TipRanks · 10/22 13:40
Jemperli FDA Approval Could Expand AnaptysBio Stock Royalty Potential
Simply Wall St · 10/21 05:38
AnaptysBio quickly drops amid hearing on GSK/Tesaro contract breach
Seeking Alpha · 10/20 19:49
CytoDyn Appoints Robert E. Hoffman As CEO; Lalezari To Focus On Research
NASDAQ · 10/20 07:28
AnaptysBio (ANAB) On Jemperli Approval Is The Royalty Story Still A Bargain
Simply Wall St · 10/20 03:28
GSK's Jemperli Becomes First Approved Immunotherapy For MSI-H/dMMR Locally Advanced Renal Cancer
NASDAQ · 10/20 03:24
AnaptysBio Shares Gain on FDA Approval for Rectal Cancer Drug
Dow Jones · 10/19 19:08
AnaptysBio notes Jemperli approved in U.S. for locally advanced rectal cancer
TipRanks · 10/19 18:25
AnaptysBio gains as GSK granted FDA label expansion for Jemperli
Seeking Alpha · 10/19 17:25
AnaptysBio Buy Rating Reiterated as Analyst Sees Strong Litigation Upside, Maintains $95 Price Target
TipRanks · 10/19 16:25
Weekly Report: what happened at ANAB last week (1012-1016)?
Weekly Report · 10/19 09:56
AnaptysBio: Fully Valued -- With Major Litigation Uncertainty
Seeking Alpha · 10/13 15:01
More
Webull provides a variety of real-time ANAB stock news. You can receive the latest news about Anaptysbio Inc through multiple platforms. This information may help you make smarter investment decisions.
About ANAB
AnaptysBio, Inc. is a royalty management company. The Company manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The Company's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The Company's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP).